Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04285723 · ClinicalTrials.gov registry record
Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum Who Have Received Alpelisib
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 57
- Enrollment target
NCT04285723 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 57 participants.
The verdict
NCT04285723 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 57 participants
- Enrollment target
Study Summary
The study was a site-based retrospective non-interventional medical chart review of pediatric and adult male and female patients with PIK3CA-Related Overgrowth Spectrum (PROS) who initiated alpelisib at least 24 weeks before the cut-off date at a MAP site. The study cut-off date was 09-Mar-2020. Patient-level data were abstracted from medical charts of all eligible patients at all participating sites. Study completion date refers to the last date data was extracted. Information from patients treated with alpelisib was used to describe the efficacy and safety of alpelisib in PROS patients.
Interventions
- OTHER alpelisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2020-06-09 |
| Est. Completion | 2021-04-16 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04285723
The ClinicalTrials.gov registry entry for NCT04285723 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which alpelisib is the first listed.
NCT04285723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04285723 about?
NCT04285723 is a clinical study titled "Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum Who Have Received Alpelisib". The study was a site-based retrospective non-interventional medical chart review of pediatric and adult male and female patients with PIK3CA-Related Overgrowth Spectrum (PROS) who initiated alpelisib at least 24 weeks before the cut-off date at a MAP site. The study cut-off date was 09-Mar-2020. Pa...
What is the current status of trial NCT04285723?
This trial is currently completed. The enrollment target is 57 participants. The study started on 2020-06-09. Estimated completion is 2021-04-16.
What interventions are being tested in trial NCT04285723?
The interventions under investigation include: alpelisib (OTHER).
Who is sponsoring clinical trial NCT04285723?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.